Skip to main content
EnglishEN
European Commission logo print header

Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis

Project description

DEENESFRITPL

Checking genes to diagnose infectious and inflammatory diseases

Arriving at any diagnosis is a complex process that involves numerous tasks, from taking an appropriate history of symptoms to conducting laboratory tests. For patients with suspected infection or inflammation, a definitive diagnosis is not always reached. The EU-funded DIAMONDS project will develop a new diagnostic classification of infectious and inflammatory diseases. This new approach, which the project calls 'personalised molecular signature diagnosis' (PMSD), will be based on the discriminatory ability of a minimal set of genes able to distinguish all common conditions simultaneously. Specifically, the project will develop a device to detect genes required for PMSD. It will do so in partnership with 22 hospitals in 11 EU countries and biotechnology groups in academia, SMEs and industry.

Objective

Our proposal will address the challenge of bringing personalised medicine into routine use in EU healthcare systems for diagnosis and treatment of common infectious and inflammatory diseases, which account for a up to a third of all medical encounters in primary care and hospital. The diagnostic process in clinical medicine has been based on recognition of a constellation of symptoms and clinical signs, supported by laboratory tests. However, a definitive diagnosis is currently made in only a minority of patients presenting to healthcare with suspected infection or inflammation. We have previously shown that individual infectious and inflammatory diseases are characterised by unique patterns of host gene expression, and that diagnosis of individual diseases can be based on small numbers of uniquely expressed genes. We propose a new diagnostic classification of infectious and inflammatory diseases, based on the discriminatory ability of a minimal set of genes, which is able to distinguish all common conditions simultaneously, an approach we call Personalised Molecular Signature Diagnosis (PMSD). In partnership with 22 hospitals in 11 EU countries, and biotechnology groups in academia, SMEs and industry, we will develop a device to detect genes required for PMSD. We will then undertake a large-scale pilot demonstration in diverse healthcare settings in Europe, to establish the benefit to patients, reduction in healthcare resource use, cost effectiveness and acceptability to patients and carers, of PMSD.

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2019-Two-Stage-RTD

Funding Scheme

IA - Innovation action

Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Net EU contribution
€ 6 577 019,75
Address
SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
SW7 2AZ LONDON
United Kingdom

See on map
Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 6 577 019,75

Participants (31)

Share this page

Download

Last update: 30 April 2024

My Booklet

Permalink: https://cordis.europa.eu/project/id/848196

European Union, 2024